Fig. 4: Dual KRAS–MAPK and PIKfyve inhibition results in metabolic crises and synergistic growth suppression in PDAC. | Nature

Fig. 4: Dual KRAS–MAPK and PIKfyve inhibition results in metabolic crises and synergistic growth suppression in PDAC.

From: Targeting PIKfyve-driven lipid metabolism in pancreatic cancer

Fig. 4: Dual KRAS–MAPK and PIKfyve inhibition results in metabolic crises and synergistic growth suppression in PDAC.The alternative text for this image may have been generated using AI.

a, Immunoblot analysis of 7940B cells treated with trametinib or MRTX1133 for 48 h. Vinculin served as a loading control. MRTX1133 and DMSO were refreshed every 12 h. b, Quantitative PCR (qPCR) of iKRAS 9805 cells after 48 h incubation with or without doxycycline (Dox) and subsequent 8-hour treatment with apilimod (AP, 50 nM), ESK981 (ESK, 300 nM) or DMSO for the genes Fasn and Acaca. Bars are ±s.d. (multiple unpaired two-tailed t-tests). c, Immunoblot analysis of iKRAS 9805 cells after 48 h incubation with or without doxycycline and subsequent 24 h treatment with apilimod (50 nM), ESK981 (300 nM) or DMSO. Vinculin served as a loading control. d, End-point pancreas + tumour weight normalized to total body weight. Pancreata of six age-matched non-tumour-bearing C57BL/6 mice were used as references. Boxes represent 25th and 75th percentiles; whiskers represent the range (one-way ANOVA with Tukey’s test); NS, not significant. e, Quantification of the proportion of PDAC in H&E sections from each tumour in d. Boxes represent 25th and 75th percentiles; whiskers represent the range (one-way ANOVA with Tukey’s test). f, Representative images of CK19 IHC staining of one tumour from each treatment arm in d. Scale bar, 5 mm. g, Tumour volumes (as a percentage of the initial volume) over the treatment course of the UM19 tumour model treated with trametinib ± ESK981. Bars show s.e.m. (two-way ANOVA with Šidák’s correction). The mice in the vehicle-treated and ESK981-treated groups are the same mice shown in Extended Data Fig. 12k–m. h, Kaplan–Meier estimates of time to tumour doubling for the mice in g (two-sided log-rank tests). i, Kaplan–Meier survival curves of KPC mice undergoing the treatments indicated (two-sided log-rank tests). The mice in the vehicle-treated and ESK981-treated groups are the same mice shown in Extended Data Fig. 12o–s. j, Tumour volumes of the KPC mice in i, measured by ultrasound.

Source Data

Back to article page